Summary of Study ST001069
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000716. The data can be accessed directly via it's Project DOI: 10.21228/M8496H This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001069 |
Study Title | Evaluation of Seryl-leucine core 1 O-glycosylated peptide (SLC1G) in TB patient urine |
Study Summary | Previous work detected an uncharacterized urine metabolite with a molecular mass of 874.3547 Da that showed promise as a biomarker for successful TB treatment. Using mass spectrometry combined with enzymatic digestions, the metabolite was structurally characterized as a seryl-leucine core 1 O-glycosylated peptide (SLC1G) of human origin. Examination of SLC1G in urine revealed a significant abundance increase in individuals with active TB versus their household contacts and healthy controls. Moreover, differential decreases in SLC1G levels were observed by week-one in TB patients during successful treatment versus those that failed treatment. The SLC1G levels also associated with clinical parameters used to measure bacterial burden (GeneXpert) and inflammation (PET-CT). These results demonstrate the importance of metabolite identification and provide strong evidence for applying SLC1G as a biomarker of TB treatment response. |
Institute | Colorado State University |
Last Name | Fitzgerald |
First Name | Bryna |
Address | 3185 Rampart Rd |
blfitz@colostate.edu | |
Phone | 9704918905 |
Submit Date | 2018-10-07 |
Raw Data Available | Yes |
Raw Data File Type(s) | d |
Analysis Type Detail | LC-MS |
Release Date | 2018-12-11 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001113 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |